Das Zentrum
Multiple Sklerose Zentrum Dresden
Patienteninformation
Kontaktinformation
Behandlungsteam
Studienteam
Neuropsychologie
Mobilitätszentrum
Das Mobilitätszentrum
Ganganalyse
Sprunganalyse
DIERS
EMIQ
Forschungsprojekte
Neuroimmunologisches Labor
Das NIL
Neurofilament-Leichtketten Analyse
Autonomes & Neuroendokrinologisches Funktionslabor
Das ANF
Untersuchungsmethoden
MS Living Lab
Management & Science
Team Management & Science
Projekte
eHealth & Analytics
MSDS 3D
MSDS Klinik & Praxis
MS-HRS
MTRS
MS Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
Deutsch
Deutsch
English (UK)
OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany
MS Treatments
Jahr
Publikationsjahr
2022
Autoren
Autorenliste der Publikation
Ziemssen T, Richter S, Mäurer M, Buttmann M, Kreusel B, Poehler AM, Lampl M, Linker RA.
Verlag
Publisher-Information
Front Neurol. 2022 Jun 27;13:913616.
Link
Zur Publikation (externer Server)
https://doi.org/10.3389/fneur.2022.913616
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
Management & Science
MSZ
Treatments
MASC
2022
RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis
Other
Jahr
2024
Patients with relapsing-remitting multiple sclerosis show accelerated whole brain volume and thalamic volume loss early in disease
Multiple Sclerosis
Jahr
2024
Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice
Multiple Sclerosis
Jahr
2024
MS brain health quality standards: a survey on the reality in clinical practice in Germany
Multiple Sclerosis
Jahr
2024
Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study
MS Treatments
Jahr
2024
